Posted by on Jun 29, 2019 in Lung cancer | 0 comments

In a nutshell

This study wants to find out how well talazoparib (Talzenna) and temozolomide (Temodal) work for treating patients with small cell lung cancer that has come back after or was unresponsive to initial chemotherapy. The main outcome that will be measured is how long the patients go before the cancer grows. The study is being conducted in California, the United States. 

The details

Talazoparib and temozolomide are anti-cancer medications. They are not usually used to treat small cell lung cancer. It is not known if using these medications as a second line therapy after initial chemotherapy has failed, will work. 

This study wants to find out how well talazoparib and temozolomide work for treating patients with unresponsive or relapsed small cell lung cancer. The main outcome that will be measured is how long the patients go before the cancer grows.

Who are they looking for?

28 patients with extensive stage small cell lung cancer are being recruited. Female participants cannot be pregnant, planning to get pregnant or be breastfeeding. Male participants must use condoms during the trial. Patients must have a tumor sample for tests and must have adequate bone marrow, liver and kidney function.

Patients cannot have received more than one prior type of treatment. Patients cannot have been treated with similar drugs to the study drugs. Patients cannot have any other serious medical issues such as heart issues, another cancer or gastrointestinal issues. 

How will it work

All of the patients will receive the same treatment. Patients will receive treatment with temozolomide on days 1-5 and talazoparib on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Response rate and survival without cancer growing will be evaluated up to 1 year.

Clinical trial locations

Locations near 20147, United States (Change):
Please enter zip/postal code and country to help us offer locations near you
Show only recruiting locations
Study ID:NCT03672773
Want personalized notifications? Get notified only when trials are matching for you.
(it's free)